Biomolecules & Therapeutics 2019; 27(6): 577-583
Functional Characterization of Pharmcogenetic Variants of Human Cytochrome P450 2C9 in Korean Populations
Myung-A Cho1, Jihoon G. Yoon2, Vitchan Kim1, Harim Kim1, Rowoon Lee1, Min Goo Lee2 and Donghak Kim1,*
1Department of Biological Sciences, Konkuk University, Seoul 05029,
2Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
Tel: +82-2-450-3366, Fax: +82-2-3436-5432
Received: July 1, 2019; Revised: July 31, 2019; Accepted: August 1, 2019; Published online: September 5, 2019.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human cytochrome P450 2C9 is a highly polymorphic enzyme that is required for drug and xenobiotic metabolism. Here, we studied eleven P450 2C9 genetic variants—including three novel variants F69S, L310V, and Q324X—that were clinically identified in Korean patients. P450 2C9 variant enzymes were expressed in Escherichia coli and their bicistronic membrane fractions were prepared The CO-binding spectra were obtained for nine enzyme variants, indicating P450 holoenzymes, but not for the M02 (L90P) variant. The M11 (Q324X) variant could not be expressed due to an early nonsense mutation. LC-MS/MS analysis was performed to measure the catalytic activities of the P450 2C9 variants, using diclofenac as a substrate. Steady-state kinetic analysis revealed that the catalytic efficiency of all nine P450 2C9 variants was lower than that of the wild type P450 2C9 enzyme. The M05 (R150L) and M06 (P279T) variants showed high kcat values; however, their Km values were also high. As the M01 (F69S), M03 (R124Q), M04 (R125H), M08 (I359L), M09 (I359T), and M10 (A477T) variants exhibited higher Km and lower kcat values than that of the wild type enzyme, their catalytic efficiency decreased by approximately 50-fold compared to the wild type enzyme. Furthermore, the novel variant M07 (L310V) showed lower kcat and Km values than the wild type enzyme, which resulted in its decreased (80%) catalytic efficiency. The X-ray crystal structure of P450 2C9 revealed the presence of mutations in the residues surrounding the substrate-binding cavity. Functional characterization of these genetic variants can help understand the pharmacogenetic outcomes.

Keywords: Cytochrome P450, P450 2C9, Diclofenac, Polymorphism, Pharmacogenetics

Cytochrome P450 (P450, CYP) is a superfamily of heme-containing enzymes and is evolutionary conserved across species (Danielson, 2002; Cho et al., 2019). Over 6,500 sequences of P450 enzymes have been reported and the number is still increasing ( P450 enzymes can utilize both endogenous and exogenous compounds, including fatty acids, sterols, carcinogens, and medicines, as their substrates (Guengerich et al., 2016). The human genome contains 57 P450 genes and 16 P450 enzymes that are primarily expressed in the liver to metabolize xenobiotics, including drugs (Guengerich, 2015).

Genetic variants of metabolic enzymes can affect drug response in patients by affecting the efficacy or toxicity of the drug. In particular, polymorphisms in human P450 enzymes can affect catalytic activity. Therefore, the metabolic outcomes of P450 genetic variants can have pharmacological and toxicological impacts on the therapeutic drugs (Lee and Kim, 2011; Jeong et al., 2018; Kim et al., 2018). Oscarson has supported the systematic nomenclature of the human P450 alleles (

The human CYP2C gene cluster is located on chromosome 10q24 with the P450s 2C8 and 2C19 (Gray et al., 1995). P450 2C9 exhibits the highest expression level in the liver along with P450 3A4 and is expressed in the small intestine, aorta, and coronary artery (Shimada et al., 1994; Delozier et al., 2007; Guengerich, 2015). P450 2C9 is also responsible for the metabolic clearance of a few drugs (15% to 20%), such as tolbutamide, diclofenac, ibuprofen, and S-warfarin (Guengerich, 2015).

P450 2C9 can be regulated on multiple levels. Inducers, such as rifampicin, dexamethasone, and phenobarbital, increase the gene expression of P450 2C9, whereas aminodarone, sulphaphenazole, and fluconazole, have been reported as a selective, competitive inhibitor of P450 2C9 (Miners and Birkett, 1998; Danielson, 2002; Nebert and Russell, 2002; Guengerich, 2015). These drugs can accelerate or delay the clearance of drugs metabolized by P450 2C9. The crystal structure of P450 2C9 published by Williams et al. (2003), can help understand the structure-function relationship of the protein. The relatively large active site of the enzyme can interact with many drug substrates. The Arg108 residue interacts with the carboxylates of some substrates (Williams et al., 2003). Structural analyses have revealed a new binding pocket for P450 2C9 resulting from an allosteric change upon interaction with warfarin (Williams et al., 2003).

The gene encoding P450 2C9 is highly polymorphic, and at least 65 alleles have been reported ( These polymorphisms include functional variants, and pharmacogenetic studies regarding the clinical effect of the alleles are important to decrease adverse drug reactions (Van Booven et al., 2010). Two of the most studied alleles are P450 2C9*2 (R144C, rs1799853) and P450 2C9*3 (I359L, rs1057910). The P450 2C9*2 and P450 2C9*3 variant alleles are present in 35% Caucasian populations, while African and Asian populations exhibit less frequencies (Van Booven et al., 2010). The P450 2C9*2 variant allele has been shown to affect the interaction between the P450 enzyme and a reductase. Moreover, the P450 2C9*3 variant allele is located in the active site of the enzyme. Thus, both alleles reduce the metabolic activity of the P450 2C9 enzyme (Crespi and Miller, 1997; Steward et al., 1997).

In this study, the genetic screening of 433 Korean patients with P450 2C9 polymorphisms was conducted and 11 allelic variants of P450 2C9, including three novel variants (F69S, L310V, and Q324X), were detected (Table 1) (Han et al., 2017). We performed functional characterization of these allelic variants of P450 2C9 containing nonsynonymous single-nucleotide polymorphisms.



Diclofenac, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, and NADP+ were purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals were of the highest commercially available grade. Escherichia coli DH5α cells were purchased from Invitrogen (Carlsbad, CA, USA).

Construction of expression vector for P450 2C9 allelic variants

The pBL vector containing the wild type P450 2C9 gene with 6× His-tag was used to construct allelic variant clones. Site-directed mutagenesis (Quick Change Lightning Site-Directed Mutagenesis Kit, Agilent Technologies, Santa Clara, CA, USA) with PCR was performed and 11 allelic variant clones were obtained using specific primers. The constructed clones with desired mutations were subcloned into the pCW bicistronic expression vector containing the NADPH-P450 reductase (NPR) gene, using NdeI and XbaI restriction enzymes (Parikh et al., 1997). The insert sequences of all constructed clones were verified by nucleotide sequencing analysis.

Expression of P450 2C9 allelic variants and preparation of bicistronic membranes

P450 2C9 wild type and its allelic variants were expressed as previously described, with minor modifications (Jeong et al., 2018; Lee et al., 2018). The pCW vectors for the P450 2C9 variants were transformed into the E. coli DH5α strain. Transformed clones were cultivated in 5 ml Luria Bertani media with 50 μg/ml ampicillin for 16 h at 37°C with shaking of 200 rpm. The clonal cultures were transferred to 500 ml terrific broth (TB) expression media with 50 μg/ml ampicillin and incubated at 37°C until the OD600 value reached 0.5. The culture was induced with 0.5 mM 5-aminolevulinic acid, 1.0 mM IPTG, 1.0 mM thiamine, and trace elements. After induction, the expression media were cultured at 25°C with shaking at 200 rpm, followed by harvesting by centrifugation after 36 h. The harvested cells were resuspended in TES buffer (pH 7.4) containing lysozyme and incubated at 4°C for 20 min. Cell pellets were centrifuged for 20 min and sonicated in 30 ml sonication buffer that contained 0.1 M potassium phosphate (pH 7.4), 20% glycerol (v/v), 6.0 mM magnesium acetate, 100 μM dithiothreitol, and 200 mM phenylmethanesulfonyl fluoride. Sonicated samples were centrifuged for 10 min at 4,000 rpm and the supernatants were transferred and ultracentrifuged for 2 h at 100,000×g. The pellet was resuspended in 10 ml of 200 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol (v/v) and was homogenized in a Dounce homogenizer. The homogenized membrane fractions were stored on ice until analysis. The CO-binding spectra of the purified membrane fractions were analyzed as previously described, with minor modifications (Guengerich et al., 2009).

Catalytic activity analysis

The catalytic activity of P450 2C9 variants was determined by measuring diclofenac hydroxylation reaction. The reaction mixture contained 0.1 μM P450 2C9 BC membrane fraction, 0.1 M potassium phosphate buffer (pH 7.4) and various concentrations of diclofenac substrate in total volume of 0.1 ml. After preincubation at 37°C for 3 min, the reaction was initiated by adding the NADPH-generating system [100 mM glucose 6-phosphate, 1 mg/ml glucose-6-phosphate dehydrogenase, and 10 mM NADP+]. Reaction mixtures were incubated for 10 min at 37°C and were then stopped by adding two volumes of pre-chilled CH3CN containing 200 ng/ml chlorpropamide as an internal standard. After vortexing, the mixture was centrifuged at 3,000 rpm for 20 min and then 100 μl of the supernatant was transferred to a glass vial and analyzed by LC-MS/MS.

The concentration of 4-hydoroxydiclofenac was measured by LC-MS/MS using Waters ACQUITY UPLCTM and Waters Quattro PremierTM. ACQUITY UPLCTM BEH C18 (2.1×50 mm, 1.7 μm) was equipped with Waters ACQUITY UPLCTM. The isocratic mobile phase comprising CH3CN and water in the ratio of 75:25 with 0.1% formic acid was pumped at a flow rate of 0.2 ml/min. An electrospray ionization source was used in the positive ion mode. The operation conditions were as follows: capillary voltage 3.9 kV, extractor voltage 3 V, RF lens 0.1 V, source temperature 150°C, dislocation gas flow 600 L/H, cone gas flow 0.0 L/hr, and collision gas flow 0.2 ml/min. The system was operated in the multiple reaction mode (MRM) to measure the peak area of compounds. The transitions of the 4-hydroxydiclofenac-H+ adduct (m/z 314.15>231.15), diclofenac-H+ adduct (m/z 296>214), and chlorpropamide-H+ adduct (m/z 277>111) were monitored at collision energies of 34, 32, and 20 eV, respectively. The QuanLynx software was used to calculate the peak area.


Expression of recombinant P450 2C9 variants in bicistronic membrane fractions

Eleven variants of P450 2C9 were successfully constructed in a pCW bicistronic vector and the recombinant P450 enzymes were expressed in E. coli. Nine variants exhibited CO-binding spectra, indicating functional P450 holoenzyme in E. coli whole cells. However, the holoenzymes for M02 variant (L90P) was not detected (data not shown). The P450 expression level of the nine variants was 80–360 nmol per liter culture, whereas that of wild type P450 2C9 was approximately 380 nmol per liter culture. In particular, the M07 (L310V) and M10 (A477T) variants exhibited decreased P450 expression, with their P450 expression of 110 and 80 nmol per liter culture, respectively. Bacterial membrane fractions containing the wild type P450 2C9, the nine variants as well as P450-NADPH reductase, were isolated (Fig. 1). The final concentrations of P450 in bicistronic membrane fractions were 0.3–2.1 μM (Fig. 1).

Diclofenac hydroxylation by P450 2C9 variants

The enzyme activity of P450 2C9 can be measured from the 4-hydroxylation reaction of diclofenac (Guengerich, 2015). LC-MS/MS analysis showed the diclofenac substrate at 1.77 min with an MRM of 296>214 and 4-hydroxydiclofenac at 1.27 min with an MRM of 314.15>231.15 (Fig. 2). The catalytic activity of the P450 2C9 variant enzymes was determined by measuring the rates of diclofenac 4-hydroxylation using bicistronic membrane fractions. Steady-state kinetic analysis of diclofenac 4-hydroxylation indicated that the catalytic efficiencies (kcat/Km) of all the variants were lower than that of the wild-type P450 2C9 (Fig. 3, Table 2). Six variants of P450 2C9, namely, M01 (F69S), M03 (R124Q), M04 (R125H), M08 (I359L), M09 (I359T), and M10 (A477T), exhibited increased Km values and decreased kcat values, thereby resulting in decreased catalytic efficiency (Fig. 3, Table 2). Of note, the M03 variant showed a dramatic decrease in its kcat value (approximately 9% of the wild type kcat value). Hence, its catalytic efficiency was 50-fold lower than that of wild type P450 2C9. A novel variant—M07 (L310V)—showed decreased kcat, but the Km value was also decreased. Therefore, its catalytic efficiency was minimally affected (approximately 80% of wild type catalytic efficiency) (Fig. 3, Table 2). Interestingly, the M05 (R150L) and M6 (P279T) variants showed increased kcat values. However, their Km values were also higher than that of the wild type enzyme (Fig. 3, Table 2).

Positions of mutated amino acids in P450 2C9 structures

Previously, the X-ray crystal structure of human P450 2C9 with bound warfarin was determined by Williams et al. (2003) (PDB ID: 1OG5). The positions of mutated amino acid residues in the P450 2C9 variants were located using the crystal structure of human P450 2C9 (Fig. 4). F69S mutation in the M01 variant is located in the loop region at the first two β strands of N-terminus (Fig. 4). L90P mutation in the M02 variant is located at the end of the B-helix and a proline mutation may induce a profound effect on the structure near the heme group, resulting in failure to express the P450 holoenzyme (Fig. 4A). The M03 and M04 variants possess mutations in the C-helix region (Fig. 4A). The R150L mutation in the M05 variant is located in the center of the D-helix (Fig. 4A). The P279T mutation in the M06 variant is located in the H-I loop (Fig. 4A). The L310V mutation in the M07 variant is located in the I-helix, but not close to the active site (Fig. 4B). The I359L or I359T mutations in the M08 and M09 variants are located at the end of K-helix and the A477T mutation in the M10 variant is present on the loop of the C-terminal β strands (Fig. 4B). Ile359 and Ala477 residues appear to form the active site of P450.


Five human P450 enzymes—CYP1A2, 2C9, 2C19, 2D6, and 3A4—are responsible for the metabolism of more than 90% clinical drugs and P450 2C9 is the second major hepatic P450 enzyme that is responsible for the metabolic clearance of 15% to 20% of drugs (Si et al., 2004; Dai et al., 2014). In particular, P450 2C9 is a polymorphic enzyme with more than 65 reported allelic variations. The high frequency of P450 2C9 polymorphism and its wide spectrum of drug metabolism makes it important to predict the outcomes of allelic variations of P450 2C9.

In this study, the recombinant variant enzymes of P450 2C9 found in Korean populations (M01–M11) were heterologously expressed in E. coli and their functional outcomes of diclofenac hydroxylation were evaluated using bicistronic membrane fractions. Three allelic variants—M01 (F69S), M07 (L310V), and M11 (Q324X)—were first found in Korean populations. One of most studied polymorphisms of P450 2C9, *3 (I359L, rs1057910), was reported with much lower frequency in Asian and African populations (Van Booven et al., 2010; Guengerich, 2015). However, our study showed the highest frequency of 6.928% in this M08 variant (Table 1).

The novel variant M01 exhibited similar expression level to that of the wild type enzyme. However, a two-fold decrease in its kcat value and a two-fold increase in its Km value resulted in 32.7% lower catalytic efficiency than the wild type enzyme. The M02 variant is P450 2C9*13 allele and was previously shown to exhibit reduced catalytic activity for all known P450 2C9 substrates (Guo et al., 2005). In this study, its recombinant holoenzyme was not expressed in E. coli. As the L90P mutation in the M02 variant at the end of the B-helix is in proximity to the heme-interacting residues (Fig. 4A), the mutation of unique proline residues may affect coordination with heme and might result in the disruption of proper folding of the P450 enzyme.

The M03 and M04 variants showed similar expression levels compared to the wild type, but their catalytic efficiency was dramatically reduced (Fig. 3, Table 2). According to a previous study, the M04 variant in the P450 2C9*14 allele showed increased Km value and significantly reduced intrinsic clearance of tolbutamide compared to the wild type enzyme (DeLozier et al., 2005). In this study, the M04 variant showed a 75% decrease in the kcat value and a two-fold increase in the Km value, which resulted in a similar decrease in the catalytic efficiency of diclofenac oxidation. The C-helix is very close to the P450-conserved heme-binding motif. Moreover, the mutations in the M03 and M04 variants are located in the C-helix (Fig. 4). Therefore, these mutations could affect the productive alignment of heme and result in marked reduction in the catalytic efficiency.

Interestingly, the M05 and M06 variants exhibited higher turn-over numbers than the wild type enzyme (Table 2). The clinical outcomes of 50% to 80% increases in turn-over numbers (albeit increases in Km values) may be critical for the metabolism of drugs with a narrow spectrum of pharmacological efficacy. The novel M07 variant contains mutations in the I-helix (Fig. 4). In P450 2C9, the I-helix is marginally kinked by interaction with the heme group, and the active site cavity is extended up from the I-helix (Fig. 4). Therefore, the substitution in the M07 variant might affect the active site cavity to alter interactions with diclofenac.

The M08 and M09 variants contain Ile359 mutations in the K-helix and are called P450 2C9*3 and *4 alleles, respectively (Sullivan-Klose et al., 1996; Imai et al., 2000). These variants exhibit poor metabolism phenotypes, such as hypersensitivity of warfarin or adverse reaction to phenytoin (Sullivan-Klose et al., 1996; Imai et al., 2000). In our study, the bicistronic membrane systems of these variants also showed a significant reduction in their catalytic efficiency (Table 2). Structural analyses revealed that the mutations in these variants could alter the residues near the active site or the substrate access channel, and result in reduced catalytic activity (Fig. 4) (Maekawa et al., 2017). In addition, the previous clinical study reported the importance of the I359L mutation in CYP2C9*3 allele, which is one of major polymorphisms affecting warfarin dose in UK Caucasians (King et al., 2004).

The M10 variant (P450 2C9*30 allele) showed a 3-fold lower expression than the wild type enzyme, a 5-fold decrease in the kcat value, and a 2-fold increase in the Km value, all of which are similar to a previous report (Maekawa et al., 2006). The catalytic efficiency of the M10 variant was much lower than that of the M04, M08, and M09 variants (Table 2). A recent study on the structural analysis of the M10 variant showed that the Ala477 residue is in the active site cavity and this substitution could alter hydrogen-bond interaction with the reoriented side chain, Gln214 (Maekawa et al., 2017).

In the M11 variant, Glu324 is substituted with a stop codon. Thus, this mutation is incapable of producing proteins. Because Glu324 is downstream of the heme-binding signature sequences of P450 2C9, the holoenzyme containing the heme prosthetic group cannot be obtained for this variant.

In conclusion, 11 allelic variants of P450 2C9 were constructed and their functional attributes were examined. Nine variants and the wild type enzyme were successfully expressed and their functional alterations toward diclofenac were analyzed. Most of these allelic variants reduced catalytic efficiency; in particular, the M03 and M10 variants showed significantly reduced catalytic efficiency. Three novel variants—M01, M07, and M11—demonstrated significant alterations in their expression or catalytic activity. As P450 2C9 is important for the metabolism of various drugs, the study of 11 variants found in Korean populations can provide valuable information on their pharmacogenetic effects.


The authors declared no conflict of interest.


This work was supported by Konkuk University in 2018.

Fig. 1. CO-binding spectra of P450 2C9 allelic variant enzymes in bicistronic membrane fractions. CO-binding spectra of P450 2C9 wild type and variants in bicistronic membrane fractions were measured, and the final concentration of the P450 holoenzyme were calculated.
Fig. 2. LC-MS/MS analysis of diclofenac hydroxylation by P450 2C9. (A) Chromatogram and fragmentation of diclofenac in the multiple reaction mode (MRM), (B) Chromatogram and fragmentation of 4-hydroxydiclofenac in the MRM. The transitions of the 4-hydroxydiclofenac-H+ adduct (m/z 314.15>231.15) and the diclofenac-H+ adduct (m/z 296>214) were monitored.
Fig. 3. Steady-state kinetic analysis of diclofenac hydroxylation by P450 2C9. Each data point is presented as the mean ± SD of triplicate assays. Steady-state kinetic parameters of diclofenac hydroxylation were calculated ().
Fig. 4. Positions of mutated amino acid residues of variants in P450 2C9 structural model. (A) Overall structure of P450 2C9, (B) Structure of the substrate-binding site. The molecular structural model of P450 2C9 was constructed using the X-ray crystal structure of human P450 2C9 with bound warfarin (PDB ID: 1OG5). The P450 2C9 structural model and mutation sites were constructed using the PyMOL software (DeLano Scientific, South San Francisco, CA, USA).

Genetic variations of P450 2C9 in Korean populationsa

P450 2C9 Variants rsID Nucleotides Changes Amino Acids Changes Reported Alleles Frequency
M01 10:96701652 T206C F69S - 0.231%
M02 rs72558187 T269C L90P *13 0.693%
M03 rs12414460 G371A R124Q *42 0.231%
M04 rs72558189 G374A R125H *14 0.231%
M05 rs7900194 G449T R150L *27 1.155%
M06 rs182132442 C835A P279T *29 0.693%
M07 10:96731969 C928G L310V - 0.231%
M08 rs1057910 A1075C I359L *3 6.928%
M09 rs56165452 T1076C I359T *4 0.231%
M10 10:96748741 G1429A A477T *30 0.426%
M11 10:96740948 C970T Q324X - 0.462%

Han et al. (2017).

Steady-state kinetic analysis of the bicistronic membranes of P450 2C9 variants

P450 2C9 Variants 4-Hydroxylation of Diclofenac

kcat, min−1 Km, μM Catalytic Efficiency (kcat/Km) Folds
WT 21.2 ± 1.0 6.0 ± 1.3 3.5 ± 0.8 1
M01 13.5 ± 1.0 11.6 ± 3.3 1.2 ± 0.3 0.33
M02 NDa NDa NDa NDa
M03 1.9 ± 0.2 25.7 ± 7.4 0.07 ±0.02 0.02
M04 5.7 ± 0.4 9.6 ± 2.5 0.6 ± 0.2 0.17
M05 32.3 ± 1.5 16.6 ± 2.6 1.9 ± 0.3 0.55
M06 38.3 ± 1.6 13.5 ± 2.0 2.8 ± 0.4 0.80
M07 8.5 ± 0.4 3.0 ± 0.7 2.8 ± 0.7 0.80
M08 16.7 ± 1.4 26.2 ± 6.3 0.6 ± 0.2 0.18
M09 12.6 ± 1.3 18.4 ± 6.3 0.7 ± 0.2 0.19
M10 4.1 ± 0.4 10.4 ± 4.1 0.4 ± 0.2 0.11
M11 NDa NDa NDa NDa

Not determined.

  1. Cho, MA, Han, S, Lim, YR, Kim, V, Kim, H, and Kim, D (2019). Streptomyces cytochrome P450 enzymes and their roles in the bio-synthesis of macrolide therapeutic agents. Biomol. Ther. (Seoul). 27, 127-133.
    Pubmed KoreaMed CrossRef
  2. Crespi, CL, and Miller, VP (1997). The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 7, 203-210.
    Pubmed CrossRef
  3. Dai, DP, Xu, RA, Hu, LM, Wang, SH, Geng, PW, Yang, JF, Yang, LP, Qian, JC, Wang, ZS, Zhu, GH, Zhang, XH, Ge, RS, Hu, GX, and Cai, JP (2014). CYP2C9 polymorphism analysis in Han Chinese populations: Building the largest allele frequency database. Pharmacogenomics J. 14, 85-92.
    Pubmed CrossRef
  4. Danielson, PB (2002). The cytochrome P450 superfamily: Biochemistry evolution and drug metabolism in humans. Curr Drug Metab. 3, 561-597.
    Pubmed CrossRef
  5. Delozier, TC, Kissling, GE, Coulter, SJ, Dai, D, Foley, JF, Bradbury, JA, Murphy, E, Steenbergen, C, Zeldin, DC, and Goldstein, JA (2007). Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 35, 682-688.
    Pubmed KoreaMed CrossRef
  6. DeLozier, TC, Lee, SC, Coulter, SJ, Goh, BC, and Goldstein, JA (2005). Functional characterization of novel allelic variants of CYP2C9 recently discovered in Southeast Asians. J Pharmacol Exp Ther. 315, 1085-1090.
    Pubmed CrossRef
  7. Gray, IC, Nobile, C, Muresu, R, Ford, S, and Spurr, NK (1995). A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 28, 328-332.
    Pubmed CrossRef
  8. Guengerich, FP (2015). Human cytochrome P450 enzymes. Cytochrome P450: Structure, Mechanism, and Biochemistry, Ortiz de Montellano, PR, ed. London: Springer, pp. 523-785
  9. Guengerich, FP, Martin, MV, Sohl, CD, and Cheng, Q (2009). Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat Protoc. 4, 1245-1251.
    Pubmed KoreaMed CrossRef
  10. Guengerich, FP, Waterman, MR, and Egli, M (2016). Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci. 37, 625-640.
    Pubmed KoreaMed CrossRef
  11. Guo, Y, Wang, Y, Si, D, Fawcett, PJ, Zhong, D, and Zhou, H (2005). Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 35, 853-861.
    Pubmed CrossRef
  12. Han, SM, Park, J, Lee, JH, Lee, SS, Kim, H, Han, H, Kim, Y, Yi, S, Cho, JY, Jang, IJ, and Lee, MG (2017). Targeted next-generation sequencing for comprehensive genetic profiling of pharmacogenes. Clin Pharmacol Ther. 101, 396-405.
    Pubmed CrossRef
  13. Imai, J, Ieiri, I, Mamiya, K, Miyahara, S, Furuumi, H, Nanba, E, Yamane, M, Fukumaki, Y, Ninomiya, H, Tashiro, N, Otsubo, K, and Higuchi, S (2000). Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics. 10, 85-89.
    Pubmed CrossRef
  14. Jeong, D, Park, HG, Lim, YR, Lee, Y, Kim, V, Cho, MA, and Kim, D (2018). Terfenadine metabolism of human cytochrome P450 2J2 containing genetic variations (G312R, P351L and P115L). Drug Metab Pharmacokinet. 33, 61-66.
    Pubmed CrossRef
  15. Kim, V, Yeom, S, Lee, Y, Park, HG, Cho, MA, Kim, H, and Kim, D (2018). In vitro functional analysis of human cytochrome P450 2A13 genetic variants: P450 2A13*2, *3, *4, and *10. J. Toxicol. Environ. Health A. 81, 493-501.
    Pubmed CrossRef
  16. King, BP, Khan, TI, Aithal, GP, Kamali, F, and Daly, AK (2004). Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics. 14, 813-822.
    Pubmed CrossRef
  17. Lee, IS, and Kim, D (2011). Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res. 34, 1799-1816.
    Pubmed CrossRef
  18. Lee, Y, Park, HG, Kim, V, Cho, MA, Kim, H, Ho, TH, Cho, KS, Lee, IS, and Kim, D (2018). Inhibitory effect of alpha-terpinyl acetate on cytochrome P450 2B6 enzymatic activity. Chem Biol Interact. 289, 90-97.
    Pubmed CrossRef
  19. Maekawa, K, Adachi, M, Matsuzawa, Y, Zhang, Q, Kuroki, R, Saito, Y, and Shah, MB (2017). Structural basis of single-nucleotide polymorphisms in cytochrome P450 2C9. Biochemistry. 56, 5476-5480.
    Pubmed KoreaMed CrossRef
  20. Maekawa, K, Fukushima-Uesaka, H, Tohkin, M, Hasegawa, R, Kajio, H, Kuzuya, N, Yasuda, K, Kawamoto, M, Kamatani, N, Suzuki, K, Yanagawa, T, Saito, Y, and Sawada, J (2006). Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics. 16, 497-514.
    Pubmed CrossRef
  21. Miners, JO, and Birkett, DJ (1998). Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 45, 525-538.
    Pubmed KoreaMed CrossRef
  22. Nebert, DW, and Russell, DW (2002). Clinical importance of the cytochromes P450. Lancet. 360, 1155-1162.
    Pubmed CrossRef
  23. Parikh, A, Gillam, EM, and Guengerich, FP (1997). Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol. 15, 784-788.
    Pubmed CrossRef
  24. Shimada, T, Yamazaki, H, Mimura, M, Inui, Y, and Guengerich, FP (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 270, 414-423.
  25. Si, D, Guo, Y, Zhang, Y, Yang, L, Zhou, H, and Zhong, D (2004). Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 14, 465-469.
    Pubmed CrossRef
  26. Steward, DJ, Haining, RL, Henne, KR, Davis, G, Rushmore, TH, Trager, WF, and Rettie, AE (1997). Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7, 361-367.
    Pubmed CrossRef
  27. Sullivan-Klose, TH, Ghanayem, BI, Bell, DA, Zhang, ZY, Kaminsky, LS, Shenfield, GM, Miners, JO, Birkett, DJ, and Goldstein, JA (1996). The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6, 341-349.
    Pubmed CrossRef
  28. Van Booven, D, Marsh, S, McLeod, H, Carrillo, MW, Sangkuhl, K, Klein, TE, and Altman, RB (2010). Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genomics. 20, 277-281.
    Pubmed KoreaMed CrossRef
  29. Williams, PA, Cosme, J, Ward, A, Angove, HC, Matak Vinkovic, D, and Jhoti, H (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 424, 464-468.
    Pubmed CrossRef

This Article

Cited By Articles

Funding Information

Social Network Service